3Lo H, Kohler JR, Di- Domenico B, et al. Nonfilamentous Candida albicans mutants are avirulent. Cell 1997,90:939-949.
4Rex JH, Pfaller MA, Walsh TJ. Antifungal susceptibihty testing:practical aspects and current challenges. Clin Microbiol Rev 2001,14:643 - 458.
5White TC, Pfaller MA, Rinaldi MG, et al. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Diseases 1997,3:102- 109.
6Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS:documentation by in vitro susceptibility testing and DNA subtype analysis[J]. Clin Infect Dis, 1994,
7White TC,Pfaller MA, Rinaldi MG, et al. Stable azole drug resistance associated with a substrain of Candida albicans from an HIVinfected patient[J]. Oral Dis, 1997,3(suppl 1) : 102- 109.
8White TC. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14α demethylase in Candida albicans[J]. Antimicrob Agents Cbemother, 1997,41(7): 1488- 1494.
9Choi W,Yoo YJ ,Kim M, et al. Identification of proteins highly expressed in the hyphae of Candida albicans by two-dimensional electrophoresis[J]. Yeast, 2003,20(12) : 1053 - 1060.
